Orchid Pharma inks manufacturing sublicense agreement with GARDP

12 Sep 2023 Evaluate

Orchid Pharma has entered into a manufacturing sublicense agreement with Global Antibiotic Research & Development Partnership (GARDP) to manufacture Cefiderocol- an antibiotic to treat certain Gram-negative infections.

This agreement is a critical step in an ambitious project by Shionogi & Co. (Shionogi), GARDP, and the Clinton Health Access Initiative (CHAI) that aims to provide access to Cefiderocol in a number of predominantly low and middle-income countries.

Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.


Orchid Pharma Share Price

668.40 -0.60 (-0.09%)
20-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.45
Dr. Reddys Lab 1280.30
Cipla 1341.45
Zydus Lifesciences 901.00
Lupin 2219.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×